AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $765,000 | -28.8% | 27,010 | -42.3% | 0.00% | -25.0% |
| Q1 2023 | $1,075,000 | -18.2% | 46,790 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $1,314,000 | -19.1% | 46,790 | -18.5% | 0.01% | -14.3% |
| Q3 2022 | $1,624,000 | +272.5% | 57,410 | +192.0% | 0.01% | +250.0% |
| Q2 2022 | $436,000 | -23.8% | 19,660 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $572,000 | +56.3% | 19,660 | +76.8% | 0.00% | +100.0% |
| Q4 2021 | $366,000 | -11.8% | 11,120 | +23.6% | 0.00% | 0.0% |
| Q3 2021 | $415,000 | -75.4% | 9,000 | -72.4% | 0.00% | -85.7% |
| Q1 2021 | $1,685,000 | +28.8% | 32,621 | +8.1% | 0.01% | +16.7% |
| Q4 2020 | $1,308,000 | +53.5% | 30,180 | +23.9% | 0.01% | +20.0% |
| Q3 2020 | $852,000 | -32.0% | 24,351 | +4.0% | 0.01% | -28.6% |
| Q2 2020 | $1,253,000 | +46.0% | 23,424 | -3.1% | 0.01% | +16.7% |
| Q1 2020 | $858,000 | -12.0% | 24,176 | +18.5% | 0.01% | +20.0% |
| Q4 2019 | $975,000 | +69.3% | 20,410 | +14.8% | 0.01% | +66.7% |
| Q3 2019 | $576,000 | -34.8% | 17,780 | +0.4% | 0.00% | -40.0% |
| Q2 2019 | $883,000 | -29.4% | 17,704 | -4.6% | 0.01% | -28.6% |
| Q1 2019 | $1,251,000 | +46.7% | 18,549 | +0.2% | 0.01% | +40.0% |
| Q4 2018 | $853,000 | -46.9% | 18,505 | -11.2% | 0.01% | -37.5% |
| Q3 2018 | $1,607,000 | -8.7% | 20,832 | -0.3% | 0.01% | -11.1% |
| Q2 2018 | $1,760,000 | +15.2% | 20,893 | +11.8% | 0.01% | +12.5% |
| Q1 2018 | $1,528,000 | +49.8% | 18,684 | +4.8% | 0.01% | +60.0% |
| Q4 2017 | $1,020,000 | -14.1% | 17,833 | +0.2% | 0.01% | -16.7% |
| Q3 2017 | $1,187,000 | -37.1% | 17,790 | -51.5% | 0.01% | +20.0% |
| Q2 2017 | $1,888,000 | +168.9% | 36,706 | +205.5% | 0.01% | +25.0% |
| Q1 2017 | $702,000 | +19.2% | 12,015 | 0.0% | 0.00% | +33.3% |
| Q4 2016 | $589,000 | +4.6% | 12,015 | +12.8% | 0.00% | 0.0% |
| Q3 2016 | $563,000 | +50.9% | 10,650 | +19.6% | 0.00% | +50.0% |
| Q2 2016 | $373,000 | -6.0% | 8,906 | -8.9% | 0.00% | -33.3% |
| Q1 2016 | $397,000 | -26.2% | 9,772 | +17.9% | 0.00% | 0.0% |
| Q4 2015 | $538,000 | -12.5% | 8,290 | -4.9% | 0.00% | -25.0% |
| Q3 2015 | $615,000 | -46.5% | 8,719 | -15.7% | 0.00% | -42.9% |
| Q2 2015 | $1,150,000 | – | 10,347 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |